Phase 4
N=615
Screening Contrast-Enhanced Mammography as an Alternative to MRI
Breast Cancer
Bottom Line
View on ClinicalTrials.gov: NCT04764292 ↗Enrolled (actual)
615
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Cancer Detection Rate (CDR) Per 1,000 Screenings — 8.3; 18.3 CDR per 1,000 screenings
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Contrast-enhanced mammography (Device); Iodinated Contrast Media (ICM) (Drug)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- Female
- Sponsor
- Wendie Berg
- Primary completion
- May 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cancer Detection Rate (CDR) Per 1,000 Screenings |
8.3; 18.3 | — |
| SECONDARY False Positive Recall Rates |
8.1; 21.6 | — |
| SECONDARY Biopsy Rate |
3.0; 11.5 | — |
| SECONDARY Positive Predictive Value of Recall (PPV1) |
9.4; 8.0 | — |
Summary
There are women for whom a screening breast MRI is clinically recommended, but not feasible either due to patient factors (body habitus, pacemaker or other implant, claustrophobia) or access (cost, other constraints). Contrast-enhanced mammography (CEM) is a potential alternative to MRI for screening that uses updated standard mammography equipment to obtain low- and high-energy images after intravenous injection of iodinated contrast (as used in CT scanning). The investigators seek to validate screening CEM as an alternative to screening MRI.
Eligibility Criteria
Inclusion Criteria
- Asymptomatic women under age 75 who are recommended for annual screening MRI and mammography based on current criteria:
- Women known to be at high risk for breast cancer because of known or suspected pathogenic mutation, prior chest radiation therapy at least 8 years earlier and before age 30, or estimated lifetime risk of at least 20% based on family history/prior biopsy history (22), between age 30 and 75.
- Women with extremely dense breasts age 40-75 (about 7% of the screening population (1)) (12).
- Women with lobular carcinoma in situ (1% of women biopsied each year; about 0.06% of our screening population) beginning the year after diagnosis.
- Women with a personal history of breast cancer diagnosed by age 50 or with dense breasts (21), beginning the year after diagnosis (will be recruited under separate ongoing TOCEM protocol).
- Women with heterogeneously dense breasts and any family history of breast cancer (about 36% of the screening population has dense breasts and about 20% have a family history of breast cancer) who do not meet current high-risk criteria, beginning at age 40 or ten years prior to the age of the youngest relative but not before age 30.
Participants are expected to have medical or other reasons that they are not able to have screening breast MRI.
Exclusion Criteria
- Under age 30 or over age 75.
- Pregnant or breast feeding.
- Breast implants.
- Breast surgery within the prior 12 months.
- Breast signs or symptoms (lump, nipple discharge, nipple retraction, or being followed for breast abnormality on prior imaging).
- Currently undergoing any type of systemic chemotherapy for cancer (excludes oral endocrine therapy such as aromatase inhibitors or tamoxifen).
- Reduced kidney function with eGFR < 45 mL/min.
Data sourced from ClinicalTrials.gov (NCT04764292). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.